Group: Management

Debra Marshall, MD, FACC

Dr. Debra Marshall is the Chief Medical Officer at ARCA Biopharma. Dr. Marshall joined ARCA in 2016 and has spent more than 20 years dedicated to cardiovascular drug development. Through her career in pharma and biotech she advanced to roles of senior leadership that involved development and approval of medicines for Heart failure, Hypertension, Acute Coronary Syndromes and Dyslipidemias. Prior to joining ARCA, she served as an Executive Medical Director in the Cardiovascular Therapeutic Area at Amgen, Senior Medical Director in Cardio-Metabolism at Genentech, Global Senior Medical Director for the CV/Acute Care team at Lilly and Associate Medical Director for CV Medical Affairs at Novartis Pharmaceutical Corporation.

Dr. Marshall holds a B.S. in Chemistry and an M.D. from the University of California, Los Angeles. She completed an internship in Internal Medicine at the University of Pennsylvania, Philadelphia and Internal Medicine residency at St Vincent Hospital in Portland, Oregon. Following a cardiology fellowship at the Oregon Health Sciences University, she served as an Assistant Professor at the University of Virginia School of Medicine in Charlottesville, an Associate Professor at the University of Los Angeles School of Medicine and held positions in private cardiology practices. Dr. Marshall has been an NIH and AHA grant recipient, was awarded a US Patent and has authored numerous scientific and clinical publications. She earned board certifications in Internal Medicine, Cardiovascular Diseases, Interventional Cardiology and Nuclear Cardiology.

Christopher D. Ozeroff

Mr. Ozeroff has been ARCA’s Senior Vice President and General Counsel since September 2004. From August 1999, Mr. Ozeroff was previously a partner with the law firm of Hogan & Hartson L.L.P., where he practiced in such areas as finance, acquisitions, public offerings and licensing. Mr. Ozeroff completed his undergraduate degree at Stanford University, and his law degree at the University of Chicago Law School.

C. Jeff Dekker

Mr. Dekker joined ARCA in May 2021 as Chief Financial Officer.  Prior to joining ARCA, Mr. Dekker served in multiple roles of increasing responsibility at GlobeImmune, Inc. from 2006 to 2021, including President, Vice President of Finance, and Senior Director, Finance and Controller. Before joining GlobeImmune, Mr. Dekker held leadership positions in finance and accounting at private software companies since 1993, including posts ranging from Corporate Controller to Vice President at Webroot Software Inc., Requisite Technology Inc. and NxTrend Technology Inc. Earlier in his career, Mr. Dekker worked at ITT Rayonier Port Angeles Pulp Division and at KPMG in Los Angeles. He earned a B.S. in accounting from Utah State University and is a certified public accountant.

Thomas A. Keuer

Mr. Keuer was appointed to his current position as Chief Operating Officer in December 2014. He joined ARCA in October 2006 as Executive Vice President, Pharmaceutical Operations. Prior to joining ARCA, Mr. Keuer held a number of senior leadership positions in the biopharmaceutical industry, including SVP of Operations for Insmed, VP of Engineering for Baxter Healthcare and VP of Operations for Somatogen. Mr. Keuer completed his undergraduate degree in chemical engineering at the University of Texas, Austin, and his M.S. degree in biochemical engineering at Rice University.

Michael R. Bristow

Dr. Bristow joined ARCA as one of ARCA’s founders in September 2004, and served as Chairman and Chief Science and Medical Officer of ARCA until he was appointed to his current position of President and Chief Executive Officer in July 2009. Dr. Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October 1991. Dr. Bristow was one of the founders of Myogen, Inc. and served as Myogen’s Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006.